All posts by imreal

Rare Disease Patient Advocates Gather in San Diego for a Week of Events to Connect, Learn, and Empower


The events that will make up the Week in RARE in San Diego this year  - RARE Health Equity Forum, RARE Advocacy Summit, and Membership and Advisory meetings.

Week in RARE events

“We are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease diagnosis.” – Charlene Son Rigby, CEO of Global Genes

Members of the rare disease community from around the world will gather in San Diego in September for Global Genes’ Week in RARE, a set of events for patient advocates to network, learn, and inspire each other.

Week in RARE includes the RARE Health Equity Forum, the RARE Advocacy Summit, the RARE Champions of Hope Awards, and meetings for Global Genes’ Global Advocacy Alliance and its RARE Corporate Alliance. The events will run successively September 18 through 21 at the Sheraton San Diego Hotel & Marina on Harbor Island Drive in San Diego.

“By bringing these events together in a single time and place, we are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease diagnosis,” said Charlene Son Rigby, CEO of Global Genes. “In addition, these events will help patients navigate the complicated landscape of healthcare more effectively, offer patient organizations solutions to expand their reach and improve their value, and allow the entire rare disease community to understand the power they have to accelerate the development of treatments and therapies.”

The RARE Health Equity Forum (formerly known as the RARE Health Equity Summit), which runs September 18 and 19, brings together rare disease stakeholders to identify ways to better serve marginalized populations. The sessions will provide attendees with actionable tools and strategic insights to support underserved and underrepresented patients within their communities.

The RARE Advocacy Summit (formerly known as the RARE Patient Advocacy Summit), one of the world’s largest gatherings for the rare disease community, runs September 19 through 21. It provides attendees with insights about the latest rare disease innovations, best practices for advocating, and actionable strategies they can use to implement and use immediately in the areas of Personal Support and Advocacy, Community Building and Sustainability, Research and Research Enablement, Collaborations in research and insights into Science innovations.

The RARE Champions of Hope Awards will be held during the RARE Advocacy Summit on September 20. The awards recognize members of the rare disease community for their innovative approaches to research, programming, and advocacy to create meaningful impact in the rare disease space.

The content and experience for attendees at both RARE Advocacy Summit and RARE Health Equity Forum will benefit rare disease patients, caregivers, patient advocacy group leaders, rare disease advocates, researchers and biopharma working in advocacy, research and contemplating how to better support patient community partners, but all are welcome.

“We hope that more attendees can take advantage of the unique content available during both events at the Week in RARE, and see the value that each event offers,” said Nicole Boice, Founder and Chief Mission Officer of Global Genes. “In addition to plenary and keynote sessions, attendees will benefit from focused tracks, working group sessions, and our new one-to-one format providing advocates time to consult with experts about a variety of topics. We want attendees to walk away with real actionable next steps that will drive progress for themselves and their communities.”

Content partners for Week in RARE include Rosamund Stone Zander Translational Neuroscience Center at Boston Children’s Hospital, Everylife Foundation, Rare Disease Diversity Coalition (RDDC), and Undiagnosed Diseases Network Foundation. A special thank you to sponsors for RARE Health Equity Forum: Champion sponsor, Travere, and Title sponsors, Genentech and Horizon and presenting sponsors for RARE Advocacy Summit: Horizon and Travere.

About Global Genes

Global Genes is a 501(c)(3) nonprofit rare disease patient advocacy organization dedicated to providing patients and advocates with a continuum of services to accelerate their path from early support and awareness through research readiness. Using a collaborative approach that involves biopharma, researchers and advocates with data as a central core, Global Genes also enables research and data collection through the RARE-X research program. Through this effort, Global Genes is building the largest collaborative patient-driven, open-data access initiative for rare diseases globally.

Share article on social media or email:

MCG, Regence, and MultiCare Connected Care Receive 2023 KLAS Points of Light Award


MCG Health, Regence Health Plans, and MultiCare Connected Care, were recognized by KLAS with the 2023 Points of Light award.

MCG Health, Regence Health Plans, and MultiCare Connected Care, were recognized by KLAS with the 2023 Points of Light award.

“MCG is humbled to stand with Regence and MultiCare Connected Care as recipients of the 2023 KLAS Points of Light award. This collaboration sets the stage for a new era in patient-centered care with evidence-based clinical decisions and timelier treatment.” – Jon Shreve, MCG President & CEO

MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, along with Regence Health Plans and MultiCare Connected Care, were recognized by KLAS with the 2023 Points of Light award. This was the first collaboration between a payer, provider, and clinical decision support vendor to produce a scalable and automated prior authorization (PA) workflow based on the HL7 Da Vinci Project’s implementation guides (IGs). The three organizations were presented with the KLAS Points of Light award during the annual KLAS K2 Summit on May 10, 2023, in Salt Lake City.

KLAS recognized MCG, Regence, and MultiCare Connected Care for utilizing interoperability standards from the HL7 Da Vinci Project to create an end-to-end HL7 FHIR® (Fast Healthcare Interoperability Resources) workflow for prior authorizations. This technology automated the submission of prior authorization requests from the provider’s electronic health record (EHR) to the payer’s medical management system and was able to return an authorization determination in real-time back to the provider’s EHR. MCG’s rules engine was integrated into the process to ensure care decisions were support by vetted, scientific evidence.

The results recognized as part of the award include:


  • 60% of auth requests were able to be completed immediately as “no auth required” and communicated to the provider via their EHR
  • 41% of requests requiring prior auth (from an initial data sample) were auto approved which meant no human review was required
  • The provider achieved 140% to 230% increase in PA productivity
  • Improved workflows for the payer and provider, leading to faster authorization decisions; Many determinations were returned in seconds, compared to a previous turnaround time of three-to-five days
  • Reduced administrative burden for stakeholders, and faster access to care for patients

MCG President and CEO, Jon Shreve, said of the recognition, “MCG is humbled to stand with Regence and MultiCare Connected Care as recipients of the 2023 KLAS Points of Light award. This collaboration sets the stage for a new era in patient-centered care with evidence-based clinical decisions and timelier treatment.”

KLAS’ annual Points of Light awards celebrate success stories—or “points of light”—achieved by payers, healthcare organizations, and vendors who have partnered to reduce costs and inefficiencies and improve the patient experience. In total, 25 collaborations were awarded a 2023 Points of Light award. The report is available to KLAS members here: https://klasresearch.com/report/points-of-light-2023-case-study-14-leveraging-hl7-fhir-interoperability-standards-to-automate-prior-authorizations/3183

###

About Regence

Regence serves more than 3.4 million people through its Regence health plans in Idaho, Oregon, Utah and Washington. Each Regence health plan is a nonprofit independent licensee of the Blue Cross and Blue Shield Association. Regence is part of a family of companies dedicated to transforming health care by delivering innovative products and services that change the way consumers nationwide experience health care. For more information, please visit regence.com.

About MultiCare Connected Care

MultiCare Connected Care (MCC) is an independent Accountable Care Organization (ACO) established in 2014 as a wholly owned subsidiary of MultiCare Health System and operates as an independent entity. It is transforming healthcare as a population health engine that represents a Clinically Integrated network (CIN) of independent & MultiCare Health System clinicians’ services across the entire social medical model of care. Under this entity, 350,000 lives are served within 30 value-based contracts.

Unlike the traditional “fee for service” health care model – where each visit, service, test, and procedure has a separate cost – MCC‘s foundation is built first and foremost on providing patient-centered, quality care at an appropriate cost. Specific measures are used to determine how well doctors, hospitals, and other providers are keeping healthy people healthy, effectively treating illnesses, and helping people better manage their chronic conditions. In this way, all the participating providers share the responsibility of providing patient-centered, high quality, efficient, cost-effective care.

MCC has established a comprehensive Clinically Integrated Network (CIN) comprised of doctors and other health care providers, as well as hospitals, clinics, and other health care services, such as imaging, labs, and pharmacies. The CIN includes independent health care professionals in the community, as well as MultiCare-employed providers, totaling over 5,100 clinicians providing services across the continuum of care. multicareconnectedcare.com

About MCG Health

MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with clinical expertise, enable its clients to prioritize and simplify their work. MCG’s world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes.

For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email:



Live Free Recovery Services Offers Detox Covered by Medicaid


Live Free Recovery Services expands to offer drug and alcohol detox in New Hampshire, providing valuable assistance to residents with financial difficulties.

Live Free Recovery Services, a popular recovery clinic with locations throughout the U.S., has announced that they are expanding to offer drug and alcohol detox in New Hampshire. Since they are one of the only clinics in the state that accepts Medicaid, this expansion will provide valuable assistance to New Hampshire residents with financial difficulties.Live Free Recovery Services is a wellness and healthcare clinic based in Manchester, New Hampshire.

Founded by recovery advocate, Ryan Gagne, the organization originally started as a sober living home. Over the years, Live Free Recovery Services has also begun offering clients other sobriety and mental wellness services. They offer inpatient and outpatient rehab along with sober living programs and halfway houses.

Clients at Live Free Recovery Services can take part in cognitive behavioral therapy, medication-assisted treatment, and other care designed to help with substance abuse disorders. The new drug and alcohol detox program is designed to help patients deal with the mental and physical effects of stopping substance abuse.

Due to the way most addictive substances work, people become physically ill or experience mental health crises when they suddenly stop taking the substance. Live Free Recovery Services will now be able to offer a safe place for clients dealing with withdrawal.

The program includes monitoring from medical professionals and healthcare for issues like seizures and vomiting. It also provides intensive psychiatric care for the extreme depression, anxiety, and other challenges patients face during withdrawal. By offering professional drug and alcohol detox, Live Free Recovery Services can help support and protect patients who are taking the first big step toward sobriety.

Offering detox means that Live Free Recovery Services can now provide patients with the same excellent care for every step of their journey.

This full-service recovery organization can help patients stay safe during withdrawal, provide therapy and treatment to help them stay sober, and offer them a safe place to live after leaving rehab. In addition to all their high-quality rehab services, Live Free Recovery Services also stands out from other clinics due to their welcoming attitude towards underprivileged clients.

They are one of the only addiction treatment centers within New Hampshire that accept Medicaid.

This Medicaid-approved detox ensures that the most vulnerable portion of the population still has access to effective, compassionate substance abuse care. Since New Hampshire Medicaid covers anyone with a disability, anyone with a diagnosed substance abuse disorder is able to get care from Live Free Recovery Services.

Instead of having to choose between staying safe and paying for food and housing, people can rely on Medicaid to cover the cost of their detox care at Live Free Recovery Services. All patients, whether covered by Medicaid or other insurance, get the same level of care at Live Free Recovery Services.

They provide thoughtful, caring assistance during what is one of the hardest times in a patient’s life.

The new drug and alcohol detox program will stay true to the company’s commitment to patient well-being. As founder Ryan Gagne explains, “You shouldn’t have to suffer while getting well in recovery from addiction.” The detox programs are situated in beautiful, natural settings with relaxing, pleasant facilities. Patients’ comfort, happiness, and satisfaction are always a priority. Live Free Recovery Services has multiple rehab and detox clinics located in Manchester and Keene. They offer specialized care for men, women, and teens, and they treat many types of addiction including alcohol, heroin, cocaine, opioid, and meth addiction.

For those interested in overcoming substance abuse, the rehab center can be reached through their website at https://livefreerecoverynh.com/contact/. They can also be contacted for admissions by calling (888) 610-2847 or emailing lfrsadmissions@livefreerecoverynh.com.

Share article on social media or email:

Gilbane Building Company Expands Healthcare Market Expertise as Angeles Garcia-Pineda joins Growing Leadership Team as Healthcare Center of Excellence Leader in the West


Angeles Garcia-Pineda

“She brings an extensive track record of success providing support to healthcare project teams during business acquisition, preconstruction and construction phases,” said Jeff Park, vice president and business leader for Gilbane Northern California.

Gilbane Building Company announced that Angeles Garcia-Pineda joined the team as Healthcare Center of Excellence (COE) Leader for the west. As a compassionate leader, Garcia-Pineda brings over 30 years of experience in the construction industry. She will leverage her expertise and relationships to help drive successful client relationships and elevate Gilbane’s focus on bringing value to our clients, trade partners, and the local community.

Garcia-Pineda will combine lessons learned and best practices from her vast experience as a premier builder of healthcare construction projects to expand Gilbane’s existing portfolio. She is passionate about creating projects that have a positive impact on our communities, while developing collaborative and trusting relationships.

“We are thrilled to have Angeles Garcia-Pineda join our leadership team in northern California. She offers notable strengths in working with partners to plan and execute strategies that support the growth and success in the healthcare sector,” said Jeff Park, vice president and business leader for Gilbane Northern California. “She brings an extensive track record of success providing support to healthcare project teams during business acquisition, preconstruction and construction phases.”

“Angeles’ deep healthcare experience brings great value to both owners and project teams,” said Paul J. Choquette III, Regional President, Gilbane Building Company. “Our investment in the West continues to grow as we provide best-in-class solutions to our clients.”

Throughout her career, Garcia-Pineda has been a champion for Lean culture and processes. She is an advocate for high standards and works closely with clients, owners, designers, architects, engineers, and authorities to ensure the successful completion of a project. She has also served as a mentor in a protégé program, providing pro bono construction management services and is proud to help facilitate projects for her community. She is a two-time recipient of the Northern California Real Estate Woman of Influence award and passionate about women in leadership roles of construction management.

“I’m thankful for the opportunity to be part of one of the leading and largest family-owned construction companies building impactful projects in our communities,” said Garcia-Pineda. “It is an honor to be part of Gilbane’s next chapter in the west as we continue to grow, forge new partnerships and expand our client base.”

Garcia-Pineda has a Bachelor of Architecture (BArch) from Tijuana Institute of Technology.

About Gilbane Building Company

Gilbane provides a full slate of construction and facilities-related services – from preconstruction planning and integrated consulting capabilities to comprehensive construction management, general contracting, design-build, and facility management services – for clients across various markets. Founded in 1870 and still a privately held, family-owned company, Gilbane has more than 45 office locations worldwide. With offices in Sacramento and San Jose, Gilbane has delivered innovative construction solutions across northern California since 1995. For more information, visit http://www.gilbaneco.com.

Share article on social media or email:

Schlafender Hase® releases TVT version 11.1 with new functionalities for an e-labelling environment


“We are harmonizing the process of proofreading in paper, paperless, or hybrid systems, and that simplifies the workflow in order to deliver accurate, up-to-date information, now and in the future, to patients and healthcare professionals” explains Mike Baird, Director of Product Development.

Schlafender Hase® announced today the release of TVT 11.1, the latest version of its industry-leading proofreading software. Functionalities integrated into TVT 11.1 simplify text verification and workflows in an electronic labelling (e-labelling) environment, in which consumers and patients typically use mobile scanning and other technologies to access product information online, often via a smartphone app.

Among its new features, TVT 11.1 includes a functionality that allows the user to compare an online version of a document, such as a Product Information Leaflet (PIL), with an approved master document by simply inserting a website URL. In addition, TVT 11.1 can also compare files in their native HTML and XML formats.

This new version follows the November 2022 release of TVT 11 and still includes powerful technology that allow users to quickly and easily upload and process documents of virtually any size. TVT 11.1 can also be augmented by optional add-on modules TVT Spelling® and TVT Artwork®. To verify readability of 1D and 2D barcodes (e.g. QR codes), TVT Barcode® can also be included.

“One of our tenets at Schlafender Hase is that our software should verify content regardless of form or format,” explains Frank Hessler, founding CEO of Schlafender Hase. “For our customers and users in Life Sciences – and that includes Regulatory Bodies themselves – the primary goal of maintaining consistency and regulatory compliance across different media, physical and online, can be easily achieved with TVT 11.1.”

“Mobile scanning and related technologies are rapidly changing how essential information is sourced and delivered,” explains Mike Baird, Director of Product Development of Schlafender Hase, “and this change is happening at a differing pace throughout the world. With TVT 11.1, we are harmonizing the process of proofreading in paper, paperless, or hybrid systems, and ultimately that simplifies the workflow in order to deliver accurate, up-to-date information, now and in the future, to patients and healthcare professionals.”

About Schlafender Hase

Schlafender Hase serves regulated industries across the globe. Clients include the world’s leading pharmaceutical and medical device companies, as well as healthcare regulatory bodies. The continued success of Schlafender Hase is based on delivering quality products and a strong understanding of customer pain points. Our easy-to-use products reduce proofreading workloads, assure the quality of printed and online materials and mitigate the risk of costly errors.

Founded in 2001, Schlafender Hase GmbH is headquartered in Frankfurt am Main, Germany, with a subsidiary in the US. More at http://www.schlafenderhase.com

Share article on social media or email:

Icahn School of Medicine at Mount Sinai Dean and Researcher Receives Prestigious Award in Psychopharmacology


“Progress in the field of pharmacological treatments for major psychiatric disorders such as schizophrenia, bipolar disorders, multiple anxiety disorder, and attention deficit disorder has been too slow compared to other serious diseases such as cancer and heart disease.” – Dr. Charney

Dennis Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System, has received the prestigious Donald Klein Lifetime Achievement Award from the American Society for Clinical Psychopharmacology (ASCP). The award was presented to Dr. Charney during the ASCP’s annual meeting on Wednesday, May 31.

The award is presented annually to an individual who has made an outstanding contribution to the field of clinical psychopharmacology. It is named in honor of Dr. Klein, who brought a rational and pragmatic approach to modern clinical psychopharmacology and the concepts behind major mood disorders. His work was fundamental not only in shaping the modern understanding of clinical depression, but also in defining the nature of clinical psychopharmacology trials.

A world-renowned expert in neurobiology and treatment of mood and anxiety disorders, Dr. Charney has made significant contributions to the understanding of and therapeutic approaches to human anxiety, fear, depression, and resilience. His work demonstrating that ketamine is a rapidly acting antidepressant has been recognized as one of the most exciting advances in antidepressant therapy in more than half a century. Most notably, Dr. Charney is named as a co-inventor on a patent for the use of ketamine as a therapeutic approach for patients with treatment-resistant depression. The treatment, which received the overwhelming support of a Food and Drug Administration panel in February 2019, has the potential to be life-changing for millions of patients with an often-devastating disease.

Elected to the Institute of Medicine of the National Academy of Sciences in 2000, Dr. Charney has been honored with every major award in his field for his research. He has also written or co-authored more than 700 publications, including groundbreaking scientific papers, chapters, and several books including Resilience: The Science of Mastering Life’s Greatest Challenges, which will be available in its third edition this September.

“Progress in the field of pharmacological treatments for major psychiatric disorders such as schizophrenia, bipolar disorders, multiple anxiety disorder, and attention deficit disorder has been too slow compared to other serious diseases such as cancer and heart disease,” said Dr. Charney. “Dr. Klein recognized that therapeutic discovery for mental illness needs a paradigm change, and he became an inspiration for me and other researchers through his groundbreaking work. It is an honor to receive this award and to continue his legacy by using new data from molecular biology, genetics, neural circuitry, and other scientific fields to identify new and novel therapies for serious mental illness.”

About the Icahn School of Medicine at Mount Sinai:

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

——————————————————-

  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Share article on social media or email:

Genomenon Acquires Boston Genetics to Accelerate Curation of Human Genome


Genomenon and Boston Genetics

“This acquisition builds on our success and puts us in the lead in the race to curate the entire human genome – bringing unprecedented actionable genomic insights for clinical diagnostic, newborn sequencing and drug development programs.” – Mike Klein, CEO

Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge and tech-enabled scientific expertise with Boston Genetics’ substantial team of genetic scientists, Genomenon is now in the lead position to be the first company to curate the entire human genome. The insights through this curation, starting with the clinical exome, will be invaluable in Genomenon’s mission to save and improve lives by making genomic information actionable.

The expanded team size and genomic expertise immediately empowers Genomenon to offer even greater support to its clinical diagnostic and pharmaceutical clients as it helps both groups understand the genomic drivers of genetic disease and oncology. In addition, the acquisition creates a genomics data service arm for Genomenon, allowing the company to provide cost-effective variant curation team extensions for genetic testing labs to speed up their turnaround times.

Genomenon CEO Mike Klein explained, “Genomenon has always been unique in our approach of combining genetic expertise with our AI-driven genomics engine, Mastermind, which has 100 times more genomic evidence and 50 times more variants than any other resource.” He continued, “We have partnered with Boston Genetics for more than three years now and have been consistently impressed with the quality of the team’s expertise and work. This acquisition builds on our success and puts us in the lead in the race to curate the entire human genome – bringing unprecedented actionable genomic insights for clinical diagnostic, newborn sequencing and drug development programs.”

Boston Genetics Co-Founder and CEO Arslan Berbic will be joining the Genomenon team as its Vice President of Business Development, Services Platform. He commented, “I am proud of the company my team and I have built with Boston Genetics and am thrilled to now have it as part of Genomenon to further power the company’s mission to curate the genome. As a member of the Genomenon team, I am excited as we work to expand our curation and variant interpretation services to our customer base by leveraging Genomenon’s AI curation engine with expert review by the Boston Genetics team.”

The acquisition, which is effective immediately, adds more than 75 highly trained genetic scientists to the Genomenon team, doubling the size of the company. Boston Genetics’ current customers include a number of top genetic testing labs across the US which will now have access to Genomenon’s AI-driven curation engine and services platform.

About Genomenon

Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

For more information, visit Genomenon.com.

About Boston Genetics:

Boston Genetics was founded in 2019 and is headquartered in Cambridge, MA with offices also across Bosnia. Its genomic interpretation services specialize in germline & somatic curation to ACMG/AMP clinical guidelines. Curators are experienced in working with bioinformatics, ClinGen and medical teams and are designed to augment customers’ variant curation teams.

For more information, visit Bostongen.com.

Share article on social media or email:

The First & Only Diagnostic Test for Periodontal Disease in Pets…


EPiQ Animal Health Announces the Distribution of OraStripdx, the Only Rapid Diagnostic Test for Periodontal Disease. Partnership Increases Access to Better Preventive Oral Health Care for Millions of…

(PRWeb June 26, 2023)

Read the full story at https://www.prweb.com/releases/the_first_only_diagnostic_test_for_periodontal_disease_in_pets_announces_distribution_partnership/prweb19411636.htm

American Canadian School of Medicine Achieves Accreditation Exceptional Facilities, Innovative Curriculum and An Esteemed Faculty Distinguishes the New Medical School


IAAR Accreditors meet with ACSOM Administration in Dominica

In an industry where securing WFME accreditors can be a challenge, American Canadian School of Medicine has achieved the remarkable feat of securing accreditation before the start of our inaugural class. This is a truly outstanding achievement

The American Canadian School of Medicine (ACSOM) is delighted to announce that it will begin its inaugural class with accreditation by the Independent Agency on Accreditation and Rating (IAAR), which is recognized by the World Federation of Medical Education (WFME). Achieving IAAR accreditation included an extensive inspection of the campus and teaching facilities, intensive review of the curriculum and a series of interviews with faculty and school leadership.

“In an industry where securing WFME accreditors can be a challenge, American Canadian School of Medicine has achieved the remarkable feat of securing accreditation before the start of our inaugural class. This is a truly outstanding achievement,” says Ramin Ahmadi, MD, MPH, founding dean of ACSOM and former associate clinical faculty at Yale School of Medicine.

The state-of-the-art teaching facilities were a significant factor in the school receiving approval by IAAR. ACSOM has classrooms and laboratories outfitted in modern technology, including simulated patient care environments that offer realistic medical experiences to support student learning and development. Traditional amenities are also offered such as a campus library, computer labs, and student lounges.

With the successful completion of the accreditation process, ACSOM is poised to launch its four-year curriculum in August. The program will start with a two-year basic sciences program in Dominica followed by two years of clinical rotations at teaching hospitals located in the United States and Canada.

“American Canadian School of Medicine is truly forward-thinking in its approach to medical education. From the beginning, students are engaged in a team-based, problem-solving learning environment where clinical medicine is intentionally integrated throughout the basic sciences curriculum,” says Ahmadi emphasizing the school’s commitment to ensuring that students are prepared for clinical medicine.

The strength of ASCOM’s curriculum is largely attributed to a dedicated team of full-time physician faculty who bring their training and experience from revered medical schools such as Yale University

School of Medicine, Weil Cornell Medical College, New York University, Penn State University’s Milton S. Hersey Medical Center, SUNY Downstate Medical Center and Western University in Canada.

With enrollment deadlines fast approaching, ACSOM is prepared to receive another surge in applicants in the upcoming weeks.

American Canadian School of Medicine

The American Canadian School of Medicine (ACSOM) is the first nonprofit international medical school in the Caribbean, with its campus based in Dominica. ACSOM offers a comprehensive medical education program with a primary focus on preparing students for residency training in North America. ACSOM is accredited by the International Agency for Accreditation and Rating (IAAR), which is recognized by the World Federation of Medical Education (WFME).

For more information about the American Canadian School of Medicine, please visit http://www.acsom.edu.dm

Share article on social media or email: